[go: up one dir, main page]

ES2023552A6 - Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid alone - Google Patents

Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid alone

Info

Publication number
ES2023552A6
ES2023552A6 ES9001566A ES9001566A ES2023552A6 ES 2023552 A6 ES2023552 A6 ES 2023552A6 ES 9001566 A ES9001566 A ES 9001566A ES 9001566 A ES9001566 A ES 9001566A ES 2023552 A6 ES2023552 A6 ES 2023552A6
Authority
ES
Spain
Prior art keywords
nimesulid
cyclodextrin
cpds
soluble
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES9001566A
Other languages
Spanish (es)
Inventor
Girona Isidro Sicart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PATPHARM HOLDING, S.A.
Original Assignee
LEETRIM Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEETRIM Ltd filed Critical LEETRIM Ltd
Priority to ES9001566A priority Critical patent/ES2023552A6/en
Priority to ITMI911396A priority patent/IT1255982B/en
Priority to DE4116659A priority patent/DE4116659C2/en
Priority to FR9106165A priority patent/FR2662360B1/en
Publication of ES2023552A6 publication Critical patent/ES2023552A6/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nimesulid inclusin cpds. (I) with betacyclodextrin alpha,beta and gamma or in their aq. are new and/or have molar ratio nimesulid:cyclodextrin 1:0.5 - 1:15. Pref. the cyclodextrin is of beta-type and. USE/ADVANTAGE - (I) shows improved bioavailability and increase the max. plasma concn. of the nimesulid, which is an antiphlogistic used in the treatment of articular and extraarticular inflammations and is very sparingly soluble and of low bioavailability. (I) have analgesic and antiphlogistic properties and are well soluble in water thus ensuring that the nimesulid is more rapidly resorbed. Suitable unit doses contain 20-150 mg (I). (9pp Dwg.No.0/3)
ES9001566A 1990-05-22 1990-05-22 Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid alone Expired - Fee Related ES2023552A6 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES9001566A ES2023552A6 (en) 1990-05-22 1990-05-22 Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid alone
ITMI911396A IT1255982B (en) 1990-05-22 1991-05-21 INCLUSION COMPOUNDS OF NIMESULIDE WITH CYCLODESTRINE AND PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS
DE4116659A DE4116659C2 (en) 1990-05-22 1991-05-22 Cyclodextrin nimesulide inclusion compounds, processes for making them and medicaments containing them
FR9106165A FR2662360B1 (en) 1990-05-22 1991-05-22 COMPOUNDS FOR INCLUDING NIMESULIDE WITH CYCLODEXTRIN, METHODS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS WITH ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY CONTAINING THE SAME.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9001566A ES2023552A6 (en) 1990-05-22 1990-05-22 Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid alone

Publications (1)

Publication Number Publication Date
ES2023552A6 true ES2023552A6 (en) 1992-01-16

Family

ID=8267635

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9001566A Expired - Fee Related ES2023552A6 (en) 1990-05-22 1990-05-22 Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid alone

Country Status (4)

Country Link
DE (1) DE4116659C2 (en)
ES (1) ES2023552A6 (en)
FR (1) FR2662360B1 (en)
IT (1) IT1255982B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1255462B (en) * 1992-07-28 1995-11-02 Grazia Maffione METHOD OF PREPARATION OF NIMESULIDE INCLUSION COMPOUNDS WITH CYCLODESTRINE
IT1291278B1 (en) * 1996-07-05 1999-01-07 Errekappa Euroterapici S P A NIMESULIDE-BASED PHARMACEUTICAL PREPARATION FOR TOPICAL USE
IN186315B (en) * 1996-12-12 2001-08-04 Panacea Biotec Ltd
IT1291895B1 (en) * 1997-04-24 1999-01-21 Errekappa Euroterapici S P A FLUID PHARMACEUTICAL PREPARATION BASED ON NIMESULIDE FOR ORAL AND RHINOPHARYNGAL USE
EP2015740A4 (en) * 2006-04-24 2009-11-11 Panacea Biotec Ltd Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR206496A1 (en) * 1972-07-03 1976-07-30 Riker Laboratories Inc PROCEDURE FOR THE PREPARATION OF 2-PHENOXY-4-NITRO-ALKYL OR HALOALKYLSULPHONANILIDES
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
DE4116659C2 (en) 2000-11-16
ITMI911396A1 (en) 1992-11-21
DE4116659A1 (en) 1991-11-28
IT1255982B (en) 1995-11-17
FR2662360B1 (en) 1993-07-30
FR2662360A1 (en) 1991-11-29
ITMI911396A0 (en) 1991-05-21

Similar Documents

Publication Publication Date Title
ATE342729T1 (en) MODIFIED TUMOR NECROSIS FACTOR
NZ501066A (en) Pharmaceutical formulations containing voriconazole and sulphobutylether beta-cyclodextrin
PT620828E (en) CYCLODEXTRIN DERIVATIVES SHOWING BETTER SOLUBILITY IN WATER AND THEIR USE
BG104680A (en) Celecoxib compositions
ATE246514T1 (en) MEDICINAL PRODUCTS CONTAINING PACLITAXEL
LU91223I2 (en) Ivabradine and its pharmaceutically acceptable derivatives (procoralan)
MY115662A (en) Novel compounds with analgesic effect
TWI265808B (en) Valdecoxib compositions
TW366342B (en) The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
MY106272A (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants.
NO962088D0 (en) Preparation for in vivo production of therapeutic products
MY119403A (en) Novel compounds with analgesic effect.
ATE193444T1 (en) FREEZE-DRIED ONDANSETRON PREPARATIONS
GR3019625T3 (en) Topically administered compositions based on high molecular weight hyaluronic acid for treating inflammations of the oral cavity, and for oral cavity hygiene and cosmetic treatment
IL146125A0 (en) Novel quinones as disease therapies
EA200400548A1 (en) TREATMENT OF HEAVY PNEUMONIA THROUGH THE INTRODUCTION OF THE TISSUE FACTOR INHIBITOR (TFPI)
ITMI911155A1 (en) HIGH VISCOSITY AND LOW PEROXIDE OXYGEN PERFLUOROPOLYETERS, AND PROCEDURE FOR THEIR PREPARATION
IT1269578B (en) MULTI-COMPONENT INCLUSION COMPLEXES WITH HIGH SOLUBILITY CONSISTING OF AN ACID TYPE DRUG, A CYCLODESTRINE AND A BASE.
IT1255723B (en) USE OF PARATORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES, FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS USEFUL IN THE PREVENTION AND THERAPY OF ABORTION AND PRETERMONE BIRTH AND IN GENERAL FOR THE TREATMENT OF GESTATION
AR005860A1 (en) AROMATIC HETERO-CYCLE COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM, AND THEIR USE.
ES2023552A6 (en) Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid alone
DE69521275D1 (en) Pharmaceutical preparations containing cefaclor
GR3015431T3 (en) Use of acetyl L-carnitine in the therapeutic treatment of coma.
ATE254851T1 (en) IODINE PRODUCTION COMPOSITION
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone

Legal Events

Date Code Title Description
PC1A Transfer granted

Owner name: PATPHARM HOLDING, S.A.

FD1A Patent lapsed

Effective date: 20050523